Romiplostim shows promise in treating chemotherapy-induced thrombocytopenia
Original story from Mass General Brigham The Phase III RECITE trial has shown that romiplostim prevents serious side…
Breakthrough in FcγRI inhibition opens path to safer autoimmune therapies
An international research group directed by UMC Utrecht have developed and characterized two first-in-class antibodies that specifically block…
Children face greater heart and inflammatory risks after COVID-19 infection than vaccination
The study is the largest of its kind in this population, and is published in The Lancet Child…